Ana Gaunt
Secretary General, IGBA
Ana Gaunt was nominated Secretary General of the International Generic and Biosimilar medicines Association (IGBA) in March 2026.
Ana brings more than 20 years of experience across the generics and biosimilar medicines sectors, with a strong background in pharmaceutical policy, market access, business development, and global programme leadership.
Ana began her career at Medicines for Europe, where she represented the generics industry in EU-level discussions on pricing, reimbursement, and access. In that role, Ana worked with European Commission bodies, health ministries, regulatory agencies, payers, and WHO-linked initiatives to help shape advocacy positions on behalf of association members.
Subsequently, Ana held senior roles at Sandoz and Novartis further deepening Ana's operational knowledge across the value chain. This included global strategic planning, country and regional portfolio and launch leadership across 17 European markets, as well as global programme management spanning market access, health economics, and digital transformation across Europe, Asia, and the Americas.
A multilingual communicator - fluent in Portuguese, English, and Spanish, with working knowledge of French, Dutch, and German - Ana brings to IGBA a perspective that combines direct association advocacy experience with a practical understanding of the challenges faced by IGBA’s member companies.
As Secretary General, Ana is committed to fostering neutrality and consensus-building across a diverse membership, and to advancing IGBA's work on regulatory harmonisation, biosimilar policy, supply chain resilience, and the contribution of generic medicines to sustainable health systems.
